Search clinical trials for: Niraparib

Total 214 results

Tesaro, Inc.

Completed

Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer

Cancer

Netherlands
Virginia Commonwealth University
GlaxoSmithKline; Puma Biotechnology, Inc.

Recruiting

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE)

Ovarian Cancer | Advanced Solid Tumor

United States
Tesaro, Inc.

Active, not recruiting

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

Neoplasms

United States
Fudan University

Recruiting

Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE)

Treatment Efficacy

China
Chongqing University Cancer Hospital

Recruiting

Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer (CQGOG0101)

Cervical Cancer

China
Abramson Cancer Center at Penn Medicine

Active, not recruiting

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Prostate Adenocarcinoma

United States
German Breast Group
GlaxoSmithKline; Stemline Therapeutics, Inc.

Not yet recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT)

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast Cancer

Germany
Sun Yat-sen University

Recruiting

Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hunan Cancer Hospital

Unknown

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

Ovarian Cancer

China
Lei Li

Recruiting

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Chemotherapy | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Niraparib | Anlotinib | CA125 | Targeted Therapy | Recurrent Ovarian Cancer

China
Fundacion CRIS de Investigación para Vencer el...
GlaxoSmithKline; Apices Soluciones S.L.; Ipsen

Active, not recruiting

Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA)

Urothelial Cancer

Spain
Zai Lab (Shanghai) Co., Ltd.

Completed

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

Ovarian Cancer

China
Institut Paoli-Calmettes
GlaxoSmithKline

Not yet recruiting

A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr (CAPRICE)

Breast Cancer
University of Pennsylvania
Bristol-Myers Squibb; GlaxoSmithKline

Active, not recruiting

Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)

Pancreatic Adenocarcinoma

United States
MedSIR

Not yet recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (ANALLISA)

Ovarian Cancer | Oligometastatic Disease | Serous Ovarian Tumor
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT); US Oncology... and other collaborators

Completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Ovarian Neoplasms | Platinum Sensitive Ovarian Cancer

United States, Belgium, Sweden, Germany, Israel, Austria, Canada, Denmark, Spain, Italy, United Kingdom, Poland, France, Hungary, Norway
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Gastric Cancer | Triple Negative Breast Cancer | Endometrial Carcinoma | Biliary Tract Carcinoma

China
University of Alabama at Birmingham

Withdrawn

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer (PARP)

Ovarian Cancer Recurrent

United States
David Liebner, MD

Withdrawn

Niraparib for the Treatment of Leiomyosarcoma

Locally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Stage III Retroperitoneal Sarcoma AJCC v8 | Stage IIIA Retroperitoneal Sarcoma AJCC v8 | Stage IIIB Retroperitoneal Sarcoma AJCC v8 | Stage IV Retroperitoneal Sarcoma AJCC v8

United States
University of Kansas Medical Center
Tesaro, Inc.

Active, not recruiting

Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial (NIRA-PANC)

Pancreatic Cancer

United States
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

Ovarian Cancer

China
Sir Mortimer B. Davis - Jewish General Hospital

Not yet recruiting

Niraparib in High-grade Endometrial Cancer Trial (NIREC)

Endometrial Cancer | Uterine Neoplasm | Serous Adenocarcinoma
Massachusetts General Hospital
GlaxoSmithKline

Recruiting

Niraparib In Recurrent IDH 1/2 Gliomas

Recurrent Glioma | Low-grade Glioma | Glioma, Malignant | IDH2 Gene Mutation | IDH1 Mutation

United States
University of Turin, Italy

Recruiting

UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)

Lung Cancer | Mesothelioma

Italy
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
Tesaro, Inc.
Merck Sharp & Dohme LLC

Completed

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)

Neoplasms | Breast Cancer | Advanced Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Peritoneal Cancer | Stage IV Breast Cancer

United States
Repare Therapeutics
Roche Pharma AG

Recruiting

Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors (ATTACC)

Advanced Solid Tumor, Adult

United States
Hospices Civils de Lyon

Recruiting

NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK)

Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer

France
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Not yet recruiting

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO)

Ovarian Cancer Recurrent

United Kingdom
OHSU Knight Cancer Institute
Eli Lilly and Company; GlaxoSmithKline; Oregon Health and Science University

Active, not recruiting

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
University Hospital Southampton NHS Foundation...
British Lung Foundation; University of Southampton

Active, not recruiting

Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)

Mesothelioma, Malignant

United Kingdom
ARCAGY/ GINECO GROUP
Tesaro, Inc.

Active, not recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)

Ovarian Carcinosarcoma | Endometrial Carcinosarcoma

France
Marc Dall'Era, MD
National Cancer Institute (NCI); Janssen, LP

Recruiting

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditions

United States
Yale University
National Institute on Aging (NIA); National Center for Research Resources (NCRR)

Completed

Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents

Bacteriuria

United States
Advanced Accelerator Applications

Completed

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Gastroenteropancreatic Neuroendocrine Tumors

United Kingdom, Italy, Netherlands, Poland
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Active, not recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian Neoplasms | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

United States, Netherlands, Spain, Finland, Italy, Poland, Belgium, Canada, France, Germany, Romania, Ukraine, Norway, United Kingdom, Israel, Greece, Denmark, Belarus, Czechia
Byondis B.V.

Completed

Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

Solid Tumor

United Kingdom, Belgium, Netherlands
Michelle S Ludwig
GlaxoSmithKline

Suspended

Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX)

Metastatic Carcinoma of the Cervix

United States
Saint Elizabeth Regional Medical Center

Withdrawn

Effect of Cranberry Extract on Infections in Burn Patients

Burn

United States
Avera McKennan Hospital & University Health Center

Active, not recruiting

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Breast Cancer | Ovarian Cancer

United States
Sun Yat-sen University

Recruiting

An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients

Recurrent/ Advanced Stage Endometrial Cancer Patients

China
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

PLATFORM Study of Precision Medicine for Rare Tumors

Rare Tumor
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient

Platinum-sensitive Relapsed Ovarian Cancer

China
Fondation Ophtalmologique Adolphe de Rothschild

Recruiting

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial (WINDOCRE)

Multiple Sclerosis

France
Sarcoma Alliance for Research through Collaboration

Completed

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

Ewing Sarcoma

United States, United Kingdom
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Ovarian Cancer

China
University Hospital, Caen

Completed

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Cancer

France
Yonsei University
Takeda

Recruiting

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor (NIRVANA-R)

Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Korea, Republic of
Tesaro, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Neoplasms

United States, Canada, Netherlands, Spain, Finland, Belgium, Germany, Israel, Denmark, Sweden, United Kingdom, Poland, Hungary, Norway, Italy, Greece, Czechia, Ukraine, Belarus, Turkey

Search clinical trials for: Niraparib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations